Vanguard Group’s BioXcel Therapeutics BTAI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$34.1K Hold
18,824
﹤0.01% 4218
2025
Q1
$38.2K Sell
18,824
-55,393
-75% -$112K ﹤0.01% 4211
2024
Q4
$444K Sell
74,217
-869
-1% -$5.2K ﹤0.01% 3972
2024
Q3
$733K Buy
75,086
+14,434
+24% +$141K ﹤0.01% 3864
2024
Q2
$1.24M Sell
60,652
-8,059
-12% -$165K ﹤0.01% 3719
2024
Q1
$3.1M Buy
68,711
+620
+0.9% +$28K ﹤0.01% 3453
2023
Q4
$3.21M Sell
68,091
-8,192
-11% -$387K ﹤0.01% 3440
2023
Q3
$3.09M Buy
76,283
+5,738
+8% +$232K ﹤0.01% 3443
2023
Q2
$7.52M Buy
70,545
+4,047
+6% +$431K ﹤0.01% 3110
2023
Q1
$19.9M Buy
66,498
+1,235
+2% +$369K ﹤0.01% 2586
2022
Q4
$22.4M Buy
65,263
+877
+1% +$301K ﹤0.01% 2568
2022
Q3
$12.2M Buy
64,386
+2,165
+3% +$409K ﹤0.01% 2855
2022
Q2
$13.1M Sell
62,221
-4,000
-6% -$845K ﹤0.01% 2842
2022
Q1
$22.2M Buy
66,221
+2,325
+4% +$778K ﹤0.01% 2708
2021
Q4
$20.8M Buy
63,896
+3,401
+6% +$1.11M ﹤0.01% 2822
2021
Q3
$29.4M Buy
60,495
+4,080
+7% +$1.98M ﹤0.01% 2652
2021
Q2
$26.2M Buy
56,415
+7,075
+14% +$3.29M ﹤0.01% 2708
2021
Q1
$34.1M Sell
49,340
-7,459
-13% -$5.15M ﹤0.01% 2516
2020
Q4
$42M Buy
56,799
+2,353
+4% +$1.74M ﹤0.01% 2292
2020
Q3
$37.8M Buy
54,446
+18,409
+51% +$12.8M ﹤0.01% 2153
2020
Q2
$30.6M Buy
36,037
+5,376
+18% +$4.56M ﹤0.01% 2228
2020
Q1
$11M Buy
30,661
+6,434
+27% +$2.3M ﹤0.01% 2575
2019
Q4
$5.66M Buy
24,227
+285
+1% +$66.6K ﹤0.01% 3130
2019
Q3
$2.7M Buy
23,942
+7,736
+48% +$871K ﹤0.01% 3348
2019
Q2
$2.84M Buy
16,206
+5,060
+45% +$887K ﹤0.01% 3367
2019
Q1
$1.76M Buy
11,146
+7,505
+206% +$1.19M ﹤0.01% 3493
2018
Q4
$224K Sell
3,641
-14,874
-80% -$915K ﹤0.01% 3883
2018
Q3
$2.27M Sell
18,515
-285
-2% -$34.9K ﹤0.01% 3486
2018
Q2
$2.77M Buy
18,800
+362
+2% +$53.3K ﹤0.01% 3401
2018
Q1
$3.02M Buy
+18,438
New +$3.02M ﹤0.01% 3324